Physician profile
Alison Sharpe
NPI 1750647731
$2,567.65
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $496 · 2021: $339 · 2022: $348 · 2023: $325 · 2024: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $633.59 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $390.82 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $294.60 | 2019-2024 | Stelara, Tremfya |
| Abbvie INC. | $284.29 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.47 | 2019-2024 | Xifaxan |
| Janssen Scientific Affairs, LLC | $115.38 | 2024 | |
| Gilead Sciences, INC. | $100.92 | 2019-2020 | |
| Lilly USA, LLC | $94.50 | 2024 | Omvoh |
| Erbe USA INC | $75.00 | 2022 | |
| Merck Sharp & Dohme LLC | $74.00 | 2019-2022 | |
| Genzyme Corporation | $62.03 | 2023-2024 | |
| Ardelyx, INC. | $52.66 | 2023-2024 | Ibsrela |
| Romark Laboratories, Lc | $51.28 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $38.71 | 2020 | |
| Shire North American Group INC | $17.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Sharpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.